{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:00:29Z","timestamp":1778878829313,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"9470","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/s0140-6736(05)66455-0","type":"journal-article","created":{"date-parts":[[2005,4,30]],"date-time":"2005-04-30T07:22:07Z","timestamp":1114845727000},"page":"1543-1551","source":"Crossref","is-referenced-by-count":553,"title":["Endometrial cancer and hormone-replacement therapy in the Million Women Study"],"prefix":"10.1016","volume":"365","member":"78","reference":[{"key":"10.1016\/S0140-6736(05)66455-0_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0029-7844(94)00383-O","article-title":"Hormone replacement therapy and endometrial cancer risk: a meta-analysis","volume":"85","author":"Grady","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/S0140-6736(05)66455-0_bib2","volume":"vol 72","year":"1999"},{"key":"10.1016\/S0140-6736(05)66455-0_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.298.6667.147","article-title":"Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestagens: results from a prospective study","volume":"298","author":"Persson","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(05)66455-0_bib4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0140-6736(91)90417-N","article-title":"Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer","volume":"338","author":"Voigt","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)66455-0_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00001648-199301000-00005","article-title":"Estrogens, progesterone and endometrial cancer","volume":"4","author":"Jick","year":"1993","journal-title":"Epidemiology"},{"key":"10.1016\/S0140-6736(05)66455-0_bib6","first-page":"265","article-title":"Estrogen replacement therapy and endometrial cancer risk: unresolved issues","volume":"81","author":"Brinton","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/S0140-6736(05)66455-0_bib7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(96)07365-5","article-title":"Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women","volume":"349","author":"Beresford","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)66455-0_bib8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/jnci\/89.15.1110","article-title":"Estrogen-progestin replacement therapy and endometrial carcinoma","volume":"89","author":"Pike","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0140-6736(05)66455-0_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/91.13.1131","article-title":"Risk of endometrial cancer following estrogen replacement therapy with and without progestins","volume":"91","author":"Weiderpass","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0140-6736(05)66455-0_bib10","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1067\/mob.2000.108081","article-title":"Continuous combined hormone replacement therapy and risk of endometrial cancer","volume":"183","author":"Hill","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/S0140-6736(05)66455-0_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1023066304473","article-title":"Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States)","volume":"14","author":"Newcomb","year":"2003","journal-title":"Cancer Causes Control"},{"key":"10.1016\/S0140-6736(05)66455-0_bib12","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jama.290.13.1739","article-title":"Effect of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures","volume":"290","author":"Anderson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(05)66455-0_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ijc.20389","article-title":"Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study","volume":"112","author":"Bakken","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/S0140-6736(05)66455-0_bib14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2004.02.003","article-title":"Carcinoma of the endometrium in patients treated with tibolone","volume":"93","author":"Yazigi","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/S0140-6736(05)66455-0_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2165\/00002018-200528030-00005","article-title":"Tibolone and endometrial cancer: a cohort and nested case-control study in the UK","volume":"28","author":"de Vries","year":"2005","journal-title":"Drug Safety"},{"key":"10.1016\/S0140-6736(05)66455-0_bib16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1046\/j.1471-0528.2002.02214.x","article-title":"Patterns of use of hormone replacement therapy in one million women in Britain, 1996\u20132000","volume":"109","year":"2002","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/S0140-6736(05)66455-0_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/bcr16","article-title":"The Million Women Study: design and characteristics of the study population","volume":"1","year":"1999","journal-title":"Breast Cancer Res"},{"key":"10.1016\/S0140-6736(05)66455-0_bib18","series-title":"International Classification of Diseases","year":"1998"},{"key":"10.1016\/S0140-6736(05)66455-0_bib19","series-title":"British National Formulary","year":"1999"},{"key":"10.1016\/S0140-6736(05)66455-0_bib20","first-page":"2102","article-title":"Fracture risk and hormone therapy in postmenopausal women","volume":"362","author":"Banks","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(05)66455-0_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","article-title":"Breast cancer and hormone replacement therapy in the Million Women Study","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(05)66455-0_bib22","series-title":"Health and deprivation: inequality and the North","author":"Townsend","year":"1988"},{"key":"10.1016\/S0140-6736(05)66455-0_bib23","author":"Beral"},{"key":"10.1016\/S0140-6736(05)66455-0_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bjc.1988.44","article-title":"The dose-effect relationship between \u2018unopposed\u2019 oestrogen and endometrial mitotiic rate: its central role in explaining and predicting endometrial cancer risk","volume":"57","author":"Key","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1016\/S0140-6736(05)66455-0_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1054\/bjoc.2001.1704","article-title":"Postmenopausal endogenous oestrogens and risk of endometrial cancer: results from a prospective study","volume":"84","author":"Zeleniuch-Jacquotte","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/S0140-6736(05)66455-0_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ijc.11529","article-title":"Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women","volume":"108","author":"Lukanova","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/S0140-6736(05)66455-0_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/ajcn\/45.1.277","article-title":"Adipose tissue as a source of hormones","volume":"45","author":"Siiteri","year":"1987","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/S0140-6736(05)66455-0_bib28","series-title":"Menopause and hormone replacement","first-page":"325","article-title":"Advice from the Committee on Safety of Medicines on hormone replacement therapy","author":"Armitage","year":"2004"},{"key":"10.1016\/S0140-6736(05)66455-0_bib29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/13595220152601837","article-title":"Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses","volume":"6","author":"Banks","year":"2001","journal-title":"J Epidemiol Biostat"},{"key":"10.1016\/S0140-6736(05)66455-0_bib30","first-page":"1543","volume":"365","year":"2005"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673605664550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673605664550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T01:53:20Z","timestamp":1550368400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673605664550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":30,"journal-issue":{"issue":"9470","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0140673605664550"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(05)66455-0","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}